Medigen Biotechnology (3176) — Cash Flow-to-Debt Ratio
Medigen Biotechnology (3176) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of NT$-18.91 Million could theoretically repay 0% of its total liabilities (NT$1.45 Billion) in one year. See Medigen Biotechnology (3176) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medigen Biotechnology Cash Flow-to-Debt Ratio (2003–2024)
Historical debt coverage capacity for Medigen Biotechnology across 12 annual periods. For the full cash flow conversion analysis, see how efficiently does Medigen Biotechnology generate cash.
Annual Cash Flow-to-Debt Ratio for Medigen Biotechnology (2003–2024)
Year-by-year debt coverage analysis for Medigen Biotechnology. Check Medigen Biotechnology earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | NT$37.92 Million | NT$1.67 Billion | ▲ +114.1% |
| 2023 | -0.16x | NT$-569.40 Million | NT$3.53 Billion | ▲ +49.8% |
| 2022 | -0.32x | NT$-1.13 Billion | NT$3.51 Billion | ▼ -210.1% |
| 2021 | 0.29x | NT$517.45 Million | NT$1.77 Billion | ▲ +171.8% |
| 2020 | -0.41x | NT$-671.38 Million | NT$1.65 Billion | ▼ -55.4% |
| 2019 | -0.26x | NT$-560.17 Million | NT$2.14 Billion | ▲ +18.3% |
| 2018 | -0.32x | NT$-529.82 Million | NT$1.66 Billion | ▼ -18.6% |
| 2017 | -0.27x | NT$-455.62 Million | NT$1.69 Billion | ▲ +26.1% |
| 2016 | -0.36x | NT$-468.61 Million | NT$1.28 Billion | ▼ -227.8% |
| 2015 | 0.29x | NT$294.18 Million | NT$1.03 Billion | ▼ -81.7% |
| 2005 | 1.56x | NT$80.72 Million | NT$51.78 Million | ▼ -61.5% |
| 2003 | 4.04x | NT$445.46 Million | NT$110.16 Million | — |